Source:http://linkedlifedata.com/resource/pubmed/id/19336998
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2009-4-1
|
| pubmed:abstractText |
High dose glucocorticoids (GC) are commonly used for the treatment of autoimmune diseases. The frequencies, occurrence day and dose-dependency for side effects may be different among the events such as diabetes mellitus, hyperlipidemia, infectious disease, osteoporosis, and peptic ulcer. We investigated GC-induced side effects in 68 patients treated with GC for autoimmune diseases. Initial dose of GC (prednisolone equivalent) was 0.67+/-0.35 mg/kg/d. Hypercholesterolemia (66%), hypertension (62%), insomnia (50%), hypertriglyceridemia (44%), excessive appetite (38%), hyperglycemia (18%), digestive symptom (16%), moon-shaped face (13%) and oral candidiasis (12%) were observed in 63 patients treated with GC. Hypercholesterolemia, excessive appetite, digestive symptom, moon-shaped face, and oral candidiasis were associated with the initial dose of prednisolone greater than 0.80 mg/kg/d. Insomnia [median 6 days (range 1-88)], excessive appetite [7 days (2-57)], hypertension [8 days (1-37)], digestive symptom [15 days (1-87)] and hypercholesterolemia [19 days (3-77)] were observed early after 6-19 days starting GC. On the other hand, hypertriglyceridemia [33 days (2-131)], oral candidiasis [35 days (7-52)] and hyperglycemia [60 days (4-134)] were developed after 33-60 days starting GC. Since the frequencies, dose-dependency and occurrence day were different among the side effects of GC, medical staffs including physicians and pharmacists should pay attention such features of the events in the treatment of autoimmune diseases.
|
| pubmed:language |
jpn
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0031-6903
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
129
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
445-50
|
| pubmed:meshHeading |
pubmed-meshheading:19336998-Adult,
pubmed-meshheading:19336998-Aged,
pubmed-meshheading:19336998-Aged, 80 and over,
pubmed-meshheading:19336998-Appetite,
pubmed-meshheading:19336998-Autoimmune Diseases,
pubmed-meshheading:19336998-Candidiasis, Oral,
pubmed-meshheading:19336998-Dose-Response Relationship, Drug,
pubmed-meshheading:19336998-Female,
pubmed-meshheading:19336998-Glucocorticoids,
pubmed-meshheading:19336998-Humans,
pubmed-meshheading:19336998-Hypercholesterolemia,
pubmed-meshheading:19336998-Hyperglycemia,
pubmed-meshheading:19336998-Hypertension,
pubmed-meshheading:19336998-Hypertriglyceridemia,
pubmed-meshheading:19336998-Male,
pubmed-meshheading:19336998-Middle Aged,
pubmed-meshheading:19336998-Prednisolone,
pubmed-meshheading:19336998-Sleep Initiation and Maintenance Disorders,
pubmed-meshheading:19336998-Young Adult
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
[Investigation of glucocorticoid-induced side effects in patients with autoimmune diseases].
|
| pubmed:affiliation |
Department of Pharmacy, Tsukuba University Hospital, Japan.
|
| pubmed:publicationType |
Journal Article,
English Abstract
|